ANTHONY J SCALZO M.D. NPI 1063491439

NPI Details

Anthony J Scalzo, M.D. is a medical oncology internal medicine in East Syracuse, NY. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Anthony J Scalzo, M.D. NPI is 1063491439. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

5008 BRITTONFIELD PKWY
SUITE 700
EAST SYRACUSE, NY
ZIP 13057
Phone: (315) 472-7504
Fax: (315) 479-8639

The NPI 1063491439 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Ct scan of chest with contrast (HCPCS:71260)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Ferritin (blood protein) level (HCPCS:82728)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Ct scan of chest without contrast (HCPCS:71250)
• Drawing of blood for a medical problem (HCPCS:99195)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Injection of drug or substance into vein (HCPCS:96374)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)

The enumeration date for this NPI number is 1/12/2006 and was last updated on 8/3/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.